张欢

中国医学科学院阜外医院 小儿外科一病区

Development and Validation of a Polygenic Risk Score for Stroke in the Chinese Population.

OBJECTIVE:To construct a polygenic risk score (PRS) for stroke and evaluate its utility in risk stratification and primary prevention for stroke.METHODS:Using a meta-analytic approach and large genome-wide association results for stroke and stroke-related traits in East Asians, we generated a combined PRS (metaPRS) by incorporating 534 genetic variants in a training set of 2,872 patients with stroke and 2,494 controls. We then validated its association with incident stroke using Cox regression models in large Chinese population-based prospective cohorts comprising 41,006 individuals.RESULTS:During a total of 367,750 person-years (mean follow-up 9.0 years), 1,227 participants developed stroke before age 80 years. Individuals with high polygenic risk had an about 2-fold higher risk of incident stroke compared with those with low polygenic risk (hazard ratio [HR] 1.99, 95% confidence interval [CI] 1.66-2.38), with the lifetime risk of stroke being 25.2% (95% CI 22.5%-27.7%) and 13.6% (95% CI 11.6%-15.5%), respectively. Individuals with both high polygenic risk and family history displayed lifetime risk as high as 41.1% (95% CI 31.4%-49.5%). Individuals with high polygenic risk achieved greater benefits in terms of absolute risk reductions from adherence to ideal fasting blood glucose and total cholesterol than those with low polygenic risk. Maintaining favorable cardiovascular health (CVH) profile could substantially mitigate the increased risk conferred by high polygenic risk to the level of low polygenic risk (from 34.6% to 13.2%).CONCLUSIONS:Our metaPRS has great potential for risk stratification of stroke and identification of individuals who may benefit more from maintaining ideal CVH.CLASSIFICATION OF EVIDENCE:This study provides Class I evidence that metaPRS is predictive of stroke risk.

9.9
1区

Neurology 2021

Adiponectin levels and risk of coronary heart disease: a meta-analysis of prospective studies.

BACKGROUND:Adiponectin is the most abundant circulating protein secreted by adipocytes. There is uncertainty about the association between adiponectin levels and risk of coronary heart disease (CHD). We conducted this meta-analysis to summarize the effect of adiponectin on the risk of CHD.METHODS:A comprehensive search was performed to identify all prospective studies on the association of adiponectin levels and risk of CHD. The quality of the eligible studies was evaluated by the Newcastle-Ottawa Scale. The fixed- or random-effects model was selected to pool the relative risk (RR) and 95% confidence interval (CI). Heterogeneity among studies was evaluated using Q test and the I² statistic. Publication bias was estimated using modified Egger's linear regression test.RESULTS:Twelve prospective studies comprising 8 nested case-control studies and 4 cohort studies were included in the meta-analysis. A total of 14,960 participants were enrolled and 4,132 incident CHD events were observed. The pooled RR for CHD was 0.83 (95% CI, 0.69-0.98, P = 0.031). Subgroup analyses showed that the pooled RRs (95% CIs) for CHD risk were 0.78 (0.66-0.92) and 0.75 (0.59-0.94) for men and women, respectively. For studies with mean age less than 65 years, the pooled RR (95% CI) for CHD risk was 0.72 (0.59-0.87). For studies with 100 or more CHD cases, the pooled RR was marginally significant (RR = 0.83, 95% CI, 0.69-1.00; P = 0.051). No publication bias was found in our study (P = 0.911).CONCLUSIONS:This meta-analysis showed that higher levels of adiponectin were associated with a low risk of CHD. The protective effect was consistently existed in men and women and in the middle-aged populations.

3.1
4区
第一作者

The American journal of the medical sciences 2013

Association between polymorphisms in the adiponectin gene and cardiovascular disease: a meta-analysis.

BACKGROUND:Previous studies have examined the associations between polymorphisms of adiponectin gene (ADIPOQ) and cardiovascular disease (CVD), but those studies have been inconclusive. The aim of this study was to access the relationship between three single nucleotide polymorphisms (SNPs), +45 T > G (rs2241766), +276 G > T (rs1501299) and -11377 C > G (rs266729) in ADIPOQ and CVD.METHODS:A comprehensive search was conducted to identify all studies on the association of ADIPOQ gene polymorphisms with CVD risk. The fixed and random effect pooled measures (i.e. odds ratio (OR) and 95% confidence interval (CI)) were calculated in the meta-analysis. Heterogeneity among studies was evaluated using Q test and the I2. Publication bias was estimated using modified Egger's linear regression test.RESULTS:Thirty-seven studies concerning the associations between the three polymorphisms of ADIPOQ gene and CVD risk were enrolled in this meta-analysis, including 6,398 cases and 10,829 controls for rs2241766, 8,392 cases and 18,730 controls for rs1501299 and 7,835 cases and 14,023 controls for rs266729. The three SNPs were significantly associated with CVD, yielding pooled ORs of 1.22 (95%CI: 1.07, 1.39; P = 0.004), 0.90 (95%CI: 0.83, 0.97; P = 0.007) and 1.09(95%CI: 1.01, 1.17; P = 0.032) for rs2241766, rs1501299 and rs266729, respectively. Rs2241766 and rs1501299 were significantly associated with coronary heart disease (CHD), yielding pooled ORs of 1.29 (95%CI: 1.09, 1.52; P = 0.004) and 0.89 (95%CI: 0.81, 0.99; P = 0.025), respectively. The pooled OR for rs266729 and CHD was 1.09 (95%CI: 0.99, 1.19; P = 0.090). Significant between-study heterogeneity was found in our meta-analysis. Evidence of publication bias was observed in the meta-analysis.CONCLUSIONS:The present meta-analysis showed that the associations between rs2241766, rs1501299 and rs266729 in the ADIPOQ and CVD were significant but weak. High quality studies are still needed to confirm the associations, especially for rs2241766.

4区
第一作者

BMC medical genetics 2012

[The analysis of drug cost and direct medical expense in community health management of hypertensive patients].

OBJECTIVE:To investigate the current situation of drug cost, hospitalization cost and direct medical expense in community health management of hypertensive patients, in order to lay foundation for evaluating whether the community health management in basic public health service has cost-effect in Health Economics.METHODS:A total of 8326 hypertensive patients from 10 survey pilots in 5 provinces were selected by cluster sampling methods, including 3967 patients who took part in community health management for over 1 year as management group and 4359 cases who have never taken part in community health management as control group. The essential information of research objects were collected by questionnaire; and the medical cost information in the last year (from November 2009 to November 2010) were collected retrospectively. The different annual medical treatment cost, hospitalization cost and direct medical expense in the two groups were compared and analyzed.RESULTS:The average annual drug cost in hypertension was (621.50 ± 1337.78) yuan per patient; while the cost was (616.13 ± 1248.40) yuan in management group and (626.44 ± 1414.30) yuan in control group respectively. The average annual drug cost of hypertensive patients who took medicine therapy was (702.05 ± 1401.79) yuan per person, while the cost in the management group ((688.50 ± 1300.70) yuan) was much lower than it in control group ((714.64 ± 1489.60) yuan). The annual average drug cost in urban was (731.88 ± 1403.31) yuan per person, which was higher than it in rural as (407.44 ± 1171.44) yuan per person. The average hospitalized rate was 12.2% (1014/8326), and the average annual cost among the hospitalized patients was (9264.47 ± 18 088.49) yuan per person; while the cost was (7583.70 ± 13 267.00) yuan in management group, which was lower than it in control group as (11 028.00 ± 21 919.00) yuan. The average annual hospitalized cost in hypertension was (1064.87 ± 6804.83) yuan per person; while the cost was (936.73 ± 5284.90) yuan in management group, which was lower than it in control group as (1181.50 ± 7937.90) yuan. The average annual direct medical expense in hypertension was (2275.08 ± 8225.66) yuan per person; while the expense was (2165.10 ± 6564.60) yuan in management group and (2375.20 ± 9487.60) yuan in control group. The average annual direct medical expense in urban ((2801.06 ± 9428.54) yuan per person) was higher than it in rural ((1254.70 ± 4990.27) yuan per person).CONCLUSION:The community health or standardized management of hypertensive patients can reduce the average annual drug cost and hospitalization cost (around 26 yuan and 245 yuan separately); and thereby save the annual direct medical expense per capita in hypertension (around 210 yuan). In the reform and development of national medical health system, we should enhance and promote the standardized community health management of hypertensive patients.

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] 2011